Department of Psychiatry, the First Affiliated Hospital of China Medical University, Shenyang, China.
Int Clin Psychopharmacol. 2012 Nov;27(6):314-20. doi: 10.1097/YIC.0b013e32835818bf.
Previous studies have implicated 5-HT1A receptor gene (HTR1A) polymorphisms in the therapeutic response to antidepressants, especially selective serotonin reuptake inhibitors. A functional HTR1A C-1019G polymorphism (rs6295) in the promoter region was found to be associated with antidepressant pharmacogenetics in different populations. However, inconsistent and inconclusive results have been obtained. In this study, we tested whether rs6295 genetic variants are related to antidepressant effects using a meta-analysis method. The relevant literature was acquired through deliberate searching and selection based on the established inclusion criteria for publications. A total of 10 articles were identified, all of which evaluated the HTR1A C-1019G polymorphism and antidepressant response. Dominant and recessive models were tested in the analyses, and the results revealed no association between the HTR1A C-1019G polymorphism and antidepressant response.
先前的研究表明，5-羟色胺 1A 受体基因（HTR1A）多态性与抗抑郁药的治疗反应有关，尤其是选择性 5-羟色胺再摄取抑制剂。在启动子区域发现的功能性 HTR1A C-1019G 多态性（rs6295）与不同人群的抗抑郁药药物遗传学有关。然而，得到的结果并不一致且没有定论。在这项研究中，我们使用荟萃分析方法来检验 rs6295 遗传变异是否与抗抑郁药的疗效有关。通过有针对性的搜索并根据已建立的出版物纳入标准进行选择，获得了相关文献。共确定了 10 篇评估 HTR1A C-1019G 多态性与抗抑郁反应的文章。在分析中测试了显性和隐性模型，结果显示 HTR1A C-1019G 多态性与抗抑郁反应之间没有关联。
